Sana Biotechnology (NASDAQ:SANA) Posts Quarterly Earnings Results

Sana Biotechnology (NASDAQ:SANA) issued its earnings results on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, FiscalAI reports.

Sana Biotechnology Trading Down 5.3%

Shares of NASDAQ SANA traded down $0.22 during mid-day trading on Tuesday, reaching $3.93. The company had a trading volume of 2,162,253 shares, compared to its average volume of 2,232,191. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -4.05 and a beta of 1.96. Sana Biotechnology has a 52 week low of $1.26 and a 52 week high of $6.55. The business’s 50-day moving average is $4.32 and its 200-day moving average is $4.14.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on SANA shares. Zacks Research raised shares of Sana Biotechnology from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. HC Wainwright cut their price objective on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Wedbush raised their target price on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, Bank of America boosted their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.17.

Hedge Funds Weigh In On Sana Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Baillie Gifford & Co. increased its position in Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after buying an additional 1,371,775 shares in the last quarter. Corient Private Wealth LLC grew its stake in shares of Sana Biotechnology by 264.7% during the second quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock worth $3,101,000 after acquiring an additional 824,505 shares during the last quarter. Marex Group plc purchased a new stake in shares of Sana Biotechnology during the second quarter worth about $10,423,000. Savant Capital LLC acquired a new position in shares of Sana Biotechnology during the second quarter valued at about $172,000. Finally, Good Life Advisors LLC purchased a new position in shares of Sana Biotechnology in the 2nd quarter valued at approximately $46,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.